Intermed Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Intermed Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Intermed Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.9M Trade | TransData Nexus

Intermed Laboratories Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $1.9M Total Trade · DGFT Verified

Intermed Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.9M across 3 products in 2 therapeutic categories. Based on 72 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Artesunate ($1.6M), Pyrimethamine ($188.6K), Glibenclamide ($92.2K).

Intermed Laboratories Private Limited — Export Portfolio & Destination Treemap

Intermed Laboratories Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Intermed Laboratories Private Limited? — Company Overview & Market Position

Intermed Laboratories Private Limited is an Indian pharmaceutical company specializing in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on October 14, 2019, in Lower Parel, Maharashtra, the company operates under the Corporate Identification Number (CIN) U24230MH2019PTC331617. The registered office is located at A-3, Floor-G, A, Todi Industrial Estate, Sitaram Jadhav Marg, Sun Mill Compound, Lower Parel, Maharashtra, 400013.

As of March 31, 2024, Intermed Laboratories reported a total revenue of ₹0.50 million, with a net worth of ₹38.16 crore. The company employs approximately 53 professionals, reflecting its commitment to quality and innovation in the pharmaceutical sector.

What Does Intermed Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Artesunate$1.6M 2Pyrimethamine

Product Portfolio — Top 3 by Export Value

Intermed Laboratories Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artesunate	Antimalarial & Antiparasitic	$1.6M	58	0.9%	10
2	Pyrimethamine	Antimalarial & Antiparasitic	$188.6K	8	0.4%	12
3	Glibenclamide	Advanced Diabetes Medications	$92.2K	6	0.2%	11

Intermed Laboratories Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $1.9M. The top category is Antimalarial & Antiparasitic (95.2% of portfolio), followed by Advanced Diabetes Medications (4.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Intermed Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Intermed Laboratories operates manufacturing facilities in Lower Parel, Maharashtra, India. The plant specializes in the production of finished pharmaceutical formulations, including oral solids (tablets and capsules), sterile parenterals (injections), eye drops, liquid orals (syrups and suspensions), dry syrups, topicals (ointments, creams, gels), transdermal patches, inhalers (metered-dose inhalers and dry powder inhalers), beta-lactam and cephalosporin products, oncology medications, and hormones.

3Key Leadership

The leadership team at Intermed Laboratories comprises:

Paresh Mehta Kirtilal: Director, appointed on August 10, 2021.

Rushabh Paresh Mehta: Director, appointed on August 24, 2021.

Riddhi Sahil Javeri: Director, appointed on October 14, 2019.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Intermed Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Intermed Laboratories has made significant strides in obtaining regulatory approvals for its products in various international markets. The company has secured approvals from the World Health Organization (WHO) for its antimalarial and antiparasitic formulations, facilitating access to markets in Africa and Southeast Asia. Additionally, Intermed Laboratories has obtained European Union Good Manufacturing Practice (EU GMP) certification, enabling it to export to European markets. The company has also filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA), aiming to enter the U.S. market. While specific approvals from the FDA are pending, these filings demonstrate the company's commitment to expanding its presence in regulated markets.

2Emerging Markets

Intermed Laboratories has strategically focused on emerging markets, particularly in Africa, Latin America, and Southeast Asia. The WHO prequalification of its antimalarial and antiparasitic products has been instrumental in gaining access to these regions, where there is a high demand for such medications. The company's adherence to international quality standards has facilitated partnerships with local distributors and healthcare providers, enhancing its market penetration in these areas.

Geographic Strategy

Intermed Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Intermed Laboratories has proactively engaged with the U.S. Food and Drug Administration (FDA) by filing Abbreviated New Drug Applications (ANDAs) for its key products, including artesunate, pyrimethamine, and glibenclamide. These filings are part of the company's strategy to enter the U.S. market, which is known for its stringent regulatory standards. While specific approvals from the FDA are pending, the company's commitment to compliance with FDA regulations underscores its dedication to quality and safety.

2WHO & EU GMP

The World Health Organization (WHO) prequalification of Intermed Laboratories' antimalarial and antiparasitic products is a testament to the company's adherence to international quality standards. This certification has facilitated access to markets in Africa and Southeast Asia, where there is a significant demand for such medications. Additionally, the company's European Union Good Manufacturing Practice (EU GMP) certification enables it to export to European markets, further expanding its global footprint.

3CDSCO & Indian Regulatory

Intermed Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Intermed Laboratories operates in a competitive landscape with several key players in the pharmaceutical export sector. Companies such as Cipla, Sun Pharma, and Dr. Reddy's Laboratories have established strong presences in both developed and emerging markets. While Intermed Laboratories holds a modest market share, its focus on specialized products like artesunate, pyrimethamine, and glibenclamide positions it uniquely to cater to specific therapeutic needs. The company's adherence to international quality standards and regulatory approvals enhances its competitiveness in the global market.

2Key Differentiators

Intermed Laboratories' key differentiators include its specialized product portfolio, particularly in the antimalarial and antiparasitic segments, and its commitment to international quality standards. The WHO prequalification of its products and EU GMP certification underscore the company's dedication to quality and safety. Additionally, the company's strategic focus on emerging markets, facilitated by its regulatory approvals, allows it to tap into regions with high unmet medical needs, providing a competitive edge in these markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Intermed Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Intermed Laboratories has demonstrated a consistent track record in exporting finished pharmaceutical formulations, with a total export value of $1.9 million USD across 72 shipments. The company's focus on specialized products, such as artesunate, pyrimethamine, and glibenclamide, reflects its commitment to addressing specific therapeutic needs. The adherence to international quality standards and regulatory approvals further underscores the company's reliability as a supplier in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification to ensure adherence to international quality standards.

Frequently Asked Questions — Intermed Laboratories Private Limited

How many pharmaceutical products does Intermed Laboratories Private Limited export from India?

Intermed Laboratories Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Artesunate ($1.6M), Pyrimethamine ($188.6K), Glibenclamide ($92.2K). Total export value is $1.9M.

What is Intermed Laboratories Private Limited's total pharmaceutical export value?

Intermed Laboratories Private Limited's total pharmaceutical export value is $1.9M, based on 72 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Intermed Laboratories Private Limited cover?

Intermed Laboratories Private Limited exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (95.2%, 2 products), Advanced Diabetes Medications (4.8%, 1 products).

Get Full Intermed Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.